New data suggest venetoclax may offset the negative prognostic impact of short telomeres in patients with chronic lymphocytic ...
In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback